Abivax (ABVX) announced that it will be added to the Nasdaq Biotechnology Index, effective prior to market open on Monday, December 22.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax price target raised to $175 from $150 at Guggenheim
- Abivax price target raised to $142 from $112 at Piper Sandler
- Abivax price target raised to $131 from $114 at Citizens
- Abivax SA Reports Increased Losses in Q3 2025 Amid Rising R&D Costs
- Options Volatility and Implied Earnings Moves Today, December 15, 2025